Search

PACK-crosslinking for infectious keratitis

Corneal cross-linking with riboflavin and UV-A light (CXL) is a technology that has been initially developed to treat corneal ectatic disorders [1]. Its effect in stabilising diseases such as keratoconus was reported in numerous trials with excellent long-term outcomes and...

Urban Changes and Rural Struggles for Ophthalmology in China

China is by far the most populated country in the world, with over 1.3 billion inhabitants. It is also the country with the highest number of blind and visually impaired people. As a developing country, half of China’s population lives...

The Story of Looking: Mark Cousins

Lake, Sweden, as featured in The Story Of Looking. In an interview with Director Mark Cousins about his relationship with sight and storytelling, Peter Cackett discusses Cousins’ recent film, The Story of Looking, and how its production informed, and was...

Myasthenia gravis presenting with isolated ptosis: a poorly studied subgroup

Investigation into the cause of one isolated symptom or sign can be challenging if that particular sign may be caused by a variety of pathological processes, affecting different tissues, and presenting to different specialties. Unilateral ptosis is a case in...

A look into the IOL space

Advances in the design and performance of intraocular lenses (IOLs) continue to be driven by demand for better outcomes, presbyopia correction and spectacle independence, alongside a better understanding of the dynamics of the crystalline lens, newer theories of accommodation and...

NICE drugs: an update on what’s good to go

Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...

Treatment of diabetic macular oedema

Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...

What’s new in glaucoma? Clinical trials drive practice changes, surgical advancements gather pace

Rod McNeil reviews the latest developments in the treatment of glaucoma in the UK. Primary open-angle glaucoma (POAG), which accounts for over two-thirds of all glaucoma cases, has an estimated UK prevalence in 2017 of approximately 2% of people over...